Article Summary
We recently published an article on the top 10 stocks that soared by double digits, including ImmunityBio, Inc. (NASDAQ:IBRX). The stock market saw large gains following a tariff truce between the US and China. ImmunityBio’s stock grew due to its impressive earnings performance, with revenues skyrocketing by 41,192% and a steady increase in the use of its immunotherapy treatment for non-muscle invasive bladder cancer.
What This Means for You
- Be aware of the potential of IBRX as an investment but consider that AI stocks may offer higher returns in a shorter time frame.
- Look for AI stocks with strong growth potential and reasonable valuations for long-term gains.
- Stay informed about global market news and its impact on individual stocks.
- Pay attention to the strategies and investments of top billionaire investors.
Original Post
We recently published a list of Why These 10 Stocks Soared by Double Digits Today. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other stocks that soared by double digits today.
The stock market kicked off the trading week brimming with optimism after the US and China announced a tariff truce on each other’s goods.
The tech-heavy Nasdaq booked the largest gains among the three major indices, rallying 4.85 percent. The S&P 500 followed with a 3.26-percent increase, and the Dow Jones, with 2.81 percent.
Over the weekend, the US and China reached a 90-day deal to lower tariffs on each other’s imports. US taxes on Chinese imports will drop to 30 percent from 145 percent previously, while China’s tariffs on US imports will drop to 10 percent from 125 percent earlier.
Beyond the major indices, 10 companies finished the week stronger, booking double-digit gains during the day. In this article, we name Monday’s 10 top performers and detail the reasons behind their strong performance.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.
Shares of ImmunityBio Inc. grew as much as 18.8 percent at intraday trading before ending the day just up by 14.01 percent at $2.36 apiece as investor sentiment was fueled by its impressive earnings performance in the first three months of the year.
In its earnings release, ImmunityBio, Inc. (NASDAQ:IBRX) said
ORIGINAL SOURCE:
Source link
